Maxim Group Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) had its price objective trimmed by Maxim Group from $5.00 to $3.00 in a research note released on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the company. HC Wainwright upped their price objective on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. D. Boral Capital reaffirmed a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research note on Friday, January 3rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $4.80.

Lineage Cell Therapeutics Stock Up 9.0 %

Shares of NYSEAMERICAN LCTX opened at $0.58 on Friday. Lineage Cell Therapeutics has a 1-year low of $0.48 and a 1-year high of $1.61. The stock has a market capitalization of $127.84 million, a price-to-earnings ratio of -4.83 and a beta of 1.16.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in Lineage Cell Therapeutics during the third quarter valued at approximately $46,000. XTX Topco Ltd acquired a new position in shares of Lineage Cell Therapeutics in the 2nd quarter valued at $61,000. GSA Capital Partners LLP bought a new stake in shares of Lineage Cell Therapeutics in the 3rd quarter valued at $84,000. Rhumbline Advisers raised its stake in Lineage Cell Therapeutics by 15.1% during the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after buying an additional 17,411 shares during the period. Finally, Barclays PLC grew its stake in Lineage Cell Therapeutics by 311.3% in the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock valued at $192,000 after acquiring an additional 159,924 shares during the period. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.